Sensei Biotherapeutics, Inc. announced that topline clinical data from the monotherapy and combination dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), will be presented in a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31 ? June 4, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6825 USD | -6.26% | -17.77% | -1.37% |
May. 14 | Stephens Starts Sensei Biotherapeutics With Overweight Rating, $5 Price Target | MT |
May. 09 | Sensei Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.37% | 16.89M | |
+16.73% | 123B | |
+13.04% | 107B | |
-5.80% | 24.01B | |
+1.69% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-14.00% | 16.23B | |
+1.18% | 13.43B | |
+24.18% | 11.32B |
- Stock Market
- Equities
- SNSE Stock
- News Sensei Biotherapeutics, Inc.
- Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting